Australian Federal Court Rules Isolated Genetic Material can be Patented
By The Guardian,
The Guardian
| 09. 04. 2014
The federal court has ruled that a company may patent genetic material that has been extracted from the human body, in a move that may have serious repercussions for the future of medical research in Australia.
Cancer Voices Australia began legal action over patents associated with a gene known as BRCA1 in 2010. Mutated versions of this gene, which women can be born with, have been associated with an increased risk of hereditary breast and ovarian cancers.
“[The patenting of this material] places limits on genetic testing, genetic research and the development of treatments and cures for genetically associated disease,” the Maurice Blackburn lawyer Rebecca Gilsenan said.
“Gene patents are of great concern to the medical research community and to the medical profession. Gene patents stifle innovation.”
In February last year the federal court ruled that genetic material associated with mutated versions of BRCA1, once isolated from the human body, could be patented. Cancer Voices Australia appealed against the decision, but on Friday the full bench of the court upheld the ruling.
The companies involved are US-based Myriad Genetics and...
Related Articles
By Geoffrey A. Fowler, The Washington Post | 07.17.2025
Nearly 2 million people protected their privacy by deleting their DNA from 23andMe after it declared bankruptcy in March. Now it’s back with the same person in charge — and I still don’t trust it.
Nor do the attorneys general...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Alice Park, TIME | 07.08.2025
Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth.
To date, there haven’t been many reliable treatment options for these babies. The few that do exist involve...
By Elizabeth Dwoskin and Yeganeh Torbati, The Washington Post | 07.16.2025
A group of well-heeled, 30-something women sat down to dinner last spring at a table set with pregnancy-friendly mocktails and orchids, ready to hear a talk about how to optimize their offspring.
Noor Siddiqui, the founder of an embryo-screening start-up...
